MedPath

Phosphatase & tensin homolog (PTEN) is a tumor supressor gene used in this study as immunohistochemistry marker for detecting loss of PTEN in Atypical Endometrial Hyperplasia and Endometrioid Endometrial Carcinoma

Not Applicable
Conditions
Health Condition 1: C541- Malignant neoplasm of endometrium
Registration Number
CTRI/2023/06/053964
Lead Sponsor
Jawaharlal Nehru Medical College, Sawangi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Cases diagnosed on biopsy or surgical specimen of endometrial carcinoma and hyperplasia with correlating clinicopathological features

Exclusion Criteria

Endometrial biopsy with inflammatory histomorphology, deficient clinical data and endometrium without representative histomorphology of precancerous and cancerous lesion

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Immunohistochemical evaluation of PTEN expression is likely to be useful in screening precancerous hyperplasia lesions & detecting earliest stage of endometrial carcinoma.Timepoint: 2 years
Secondary Outcome Measures
NameTimeMethod
To assess whether PTEN is a feasible marker or not.Timepoint: 2 years
© Copyright 2025. All Rights Reserved by MedPath